Atara Biotherapeutics (NASDAQ:ATRA) Raised to “Strong-Buy” at RODMAN&RENSHAW

Atara Biotherapeutics (NASDAQ:ATRA) was upgraded by equities research analysts at RODMAN&RENSHAW to a “strong-buy” rating in a research note issued on Friday,Zacks.com reports.

ATRA has been the subject of several other reports. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Rodman & Renshaw started coverage on shares of Atara Biotherapeutics in a research note on Friday. They issued a “buy” rating and a $25.00 price target for the company. Finally, Canaccord Genuity Group upped their target price on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, three have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $18.75.

Atara Biotherapeutics Trading Up 14.8 %

Shares of Atara Biotherapeutics stock opened at $11.40 on Friday. The stock has a market cap of $65.66 million, a price-to-earnings ratio of -0.44 and a beta of 0.55. Atara Biotherapeutics has a twelve month low of $6.50 and a twelve month high of $39.50. The company has a fifty day moving average price of $10.80 and a 200 day moving average price of $9.57.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analyst estimates of $23.00 million. During the same quarter in the prior year, the business earned ($16.50) EPS. Analysts forecast that Atara Biotherapeutics will post -12.12 earnings per share for the current year.

Institutional Trading of Atara Biotherapeutics

Several hedge funds have recently added to or reduced their stakes in the business. Point72 Asia Singapore Pte. Ltd. bought a new position in Atara Biotherapeutics during the second quarter valued at about $53,000. Cubist Systematic Strategies LLC purchased a new position in Atara Biotherapeutics in the 2nd quarter worth about $79,000. State Street Corp boosted its position in shares of Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 7,680 shares during the period. FMR LLC raised its holdings in shares of Atara Biotherapeutics by 41.7% during the 3rd quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 7,381 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of Atara Biotherapeutics by 9.5% during the third quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after acquiring an additional 4,043 shares in the last quarter. Institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.